There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.
**NM signifies a non meaningful value. A dash signifies the data is not available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback